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Facioscapulohumeral muscular dystro-phy (FSHD) is a progressive myopa-
thy with a relatively late age of onset 
(usually in the late teens) compared with 
Duchenne and many other muscular 
dystrophies. The current FSHD disease 
model postulates that contraction of the 
D4Z4 array at chromosome 4q35 leads 
to a more open chromatin conformation 
in that region and allows transcription of 
the DUX4 gene. DUX4 mRNA is stable 
only when transcribed from certain hap-
lotypes that contain a polyadenylation 
signal. DUX4 protein is hypothesized 
to cause FSHD by mediating cytotoxic-
ity and impairing skeletal muscle differ-
entiation. We recently showed in a cell 
culture model that DUX4 expression is 
regulated by telomere length, suggest-
ing that telomere shortening during 
aging may be partially responsible for 
the delayed onset and progressive nature 
of FSHD. We here put our data in the 
context of other recent findings arguing 
that progressive telomere shortening may 
play a critical role in FSHD but is not the 
whole story and that the current disease 
model needs additional refinement.
Facioscapulohumeral muscular dystro-
phy (FSHD, FSHD1A MIM 158900) has 
been linked to a reduction in size of the 
D4Z4-array at chromosome 4q (reviewed 
in1). Healthy individuals have up to 150 
of these macrosatellite repeats (each 3.3 
kb in length), whereas in FSHD patients 
this number is reduced to less than 11. 
Short D4Z4 arrays lose marks of hetero-
chromatin, such as DNA methylation and 
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histone H3K9 methylation (reviewed in1). 
It has been proposed that D4Z4 repeat 
contraction is pathogenic only on spe-
cific, so called permissive haplotypes, i.e., 
in the presence of the A-allele (but not 
B- or C-alleles) distal to D4Z4,2 and one 
of several SSLP (simple sequence length 
polymorphisms) proximal to D4Z4 (161, 
161L, 159, or 168).3 A-type alleles contain 
the pLAM region harboring a polyadenyl-
ation signal for transcripts from the most 
telomeric D4Z4 unit.3,4 Each D4Z4 unit 
contains an evolutionarily conserved ORF 
for DUX4,5 suggesting that its gene prod-
uct has an important function. Indeed, 
DUX4 has been found to be expressed 
not only in FSHD muscle,6,7 where it pre-
sumably contributes to pathology, but also 
in human testes and iPS cells,7 where it 
presumably has beneficial, yet unknown 
functions. The “DUX4-model” is the lat-
est and most attractive in a long series of 
candidates thought to explain the molec-
ular pathogenesis of FSHD. Increasing 
amounts of data support this model, but 
important aspects of the molecular patho-
genesis of FSHD are still missing and sev-
eral reports contain cases that cannot be 
explained by the current model. DUX4 
expression is found in only ~1:1,000–
2,000 nuclei in myotubes from FSHD 
samples.6,7 Although possible, it appears 
biologically implausible that this isolated 
expression would cause the observed 
myopathy. FSHD has the characteristics 
of a complex, multifactorial disease and 
the evidence is exceptionally strong that 
“DUX4 expression from a contracted 
and permissive 4q allele” is not generally 
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achieve higher percentages of DUX4-
positive nuclei in differentiated myotubes 
(more than 10% in some cases). Prolonged 
differentiation resulted in apoptosis of 
myotubes from FSHD cell lines, which 
impressively could be prevented by DUX4 
knock down. However, four out of ten 
FSHD cell lines did not show the apop-
totic phenotype, including one with a 
high percentage of DUX4-positive nuclei. 
These observations again indicate that 
heterogeneous pathways are active in 
FSHD cells from different patients. In 
contrast, inappropriate activation of some 
DUX4 target genes21 in FSHD muscle has 
been independently confirmed in a large 
cohort.19 To summarize, the functions of 
endogenous DUX4 and how it may cause 
or contribute to FSHD are still largely cor-
relative. In addition, expression patterns 
of DUX4 in muscle biopsies reveal a com-
plex picture, incompatible with the simple 
model that DUX4 is expressed exclusively 
in FSHD muscle where it causes disease. 
First, full length DUX4 mRNA is not 
exclusively found in FSHD muscle. It is 
also observed in a significant subset of 
controls with normal sized D4Z4 repeats 
and no sign of muscle disease (ref. 6: 3 out 
of 26). Second, full length DUX4 mRNA 
is not detected in all muscle biopsies from 
FSHD subjects [5 out of 10 (ref. 7), and 
13 out of 59 (ref. 6) FSHD samples had 
no DUX4 detected]. Third, muscle weak-
ness in FSHD subjects does not strongly 
correlate with DUX4 expression: DUX4 
was present in several subjects contain-
ing contracted D4Z4 on a permissive 
allele, but without clinical manifestations 
of the disease.6 Finally, DUX4 expression 
was absent in some FSHD muscles show-
ing clear signs of weakness.6 We therefore 
conclude that the presence of DUX4 in 
skeletal muscle is not by itself sufficient 
to cause FSHD in most cases. However, it 
is possible that transient bursts of DUX4 
expression may cause or contribute to 
FSHD while being undetectable at a cer-
tain time or area of biopsy, as speculated 
before.7
Because detectable DUX4 apparently 
does not cause disease in some individu-
als, we postulate there often needs to be 
involvement of at least a second factor in 
the etiology of FSHD. Theoretically, there 
might be protective factors preventing 
with the B allele and chromosome 10 
have been detected in human testes,7 the 
latter using a polyadenylation signal ~6.5 
kb distal of pLAM. If these transcripts 
are stable enough to be detected in testes, 
transcription and translation from “non-
permissive” alleles might also be possible 
in skeletal muscle. Hence, expanding the 
sample size expanded the number of hap-
lotypes on 4q that are compatible with 
FSHD, and revealed that only a small 
percentage of carriers of contracted and 
permissive alleles develop disease. These 
observations are still compatible with the 
notion that inappropriate DUX4 expres-
sion in skeletal muscle contributes to 
FSHD. However, definitive proof that 
DUX4 is the primary cause of FSHD is 
still missing. Cytotoxicity has been shown 
mostly in overexpression studies and is not 
specific to muscle (e.g., 14-17). In addi-
tion, differentiation of myoblasts induces 
not only endogenous DUX4,18 but also a 
mechanism rendering them more resis-
tant to overexpressed DUX4.14 This is 
consistent with our observations showing 
no obvious increase in cell death in dif-
ferentiating FSHD cells with short telo-
meres (with higher endogenous DUX4 
expression) compared with isogenic cells 
with long telomeres (and lower DUX4 
expression), or cells from unaffected sib-
lings with no detectable DUX4. Apoptosis 
genes were not upregulated in cells with 
high endogenous DUX4 expression due to 
short telomeres, in contrast to data gener-
ated after ectopic DUX4 overexpression 
by others (e.g., BAX, BID, TP5316). On 
the molecular level, we also could not 
detect any inhibition of myogenic differ-
entiation by endogenously high DUX4 
levels, as opposed to ectopic overexpres-
sion. Similarly, transcriptional profiling 
of muscle biopsies from FSHD subjects, 
most of which express DUX4,6 show only 
few and mild differences when compared 
with unaffected siblings,19 without major 
changes in apoptosis genes or skeletal 
muscle differentiation markers. Therefore 
it is entirely possible that strong cyto-
toxicity and inhibition of differentiation 
was an artifact of ectopic overexpression. 
Recently, the first indirect evidence that 
endogenous DUX4 may trigger apoptosis 
in vitro has been reported.20 The authors 
optimized cellular culture conditions to 
sufficient and may not even be necessary 
to cause FSHD. Instead we envision a two 
(or more) hit mechanism, where the first 
hit is a contracted allele (causing misex-
pression of DUX4 in most cases), and the 
second the co-occurrence of one of sev-
eral conditions: contraction of the second 
D4Z4 allele on 4q8 (or the presence of 
only 1–3 repeats, where DUX4 expression 
may be unusually high even with monoal-
lelic genetics), an independent myopathy, 
a family background of high CRYM or 
other muscle-toxic protein expression,9 or 
an unusually short telomere at the con-
tracted 4q. It is also conceivable that low 
levels of SMCHD1, which cause the rare 
contraction-independent form of FSHD 
(FSHD2, MIM 158901),10 represents a 
second hit in some patients with the much 
more common contraction-dependent 
FSHD.
We want to emphasize that many 
candidates for the cause of FSHD were 
discovered in a small set of samples and, 
though they may be relevant for particular 
FHSD cases, these findings often have not 
generalized to larger populations, becom-
ing non-significant when the sample size 
increased. In carefully planned cell cul-
ture studies it was shown that for several 
readouts, there were bigger differences 
between families (each with FSHD and 
unaffected individuals) than between 
FSHD and unaffected individuals within 
families.11 Hence, these family effects may 
lead to misinterpretation of small data 
sets.
Testing more than 800 independent 
and healthy individuals from Italy and 
Brazil, the previously described permissive 
allele (contracted D4Z4 on 4qA161 with 
a polyadenylation site) was found with an 
unexpectedly high frequency (1.4%), two 
orders of magnitude higher than the inci-
dence of FSHD.12 This clearly argues that 
the permissive signature is not sufficient to 
cause disease. In addition, these numbers 
are probably underestimates, as several 
other haplotypes previously described as 
“non-permissive” did not prevent disease 
in ~25% of 223 FSHD patients, includ-
ing the 4qA166 haplotype (which had 
been suggested to be nonpathogenic in the 
Dutch population13), but also the B-type-
allele that lacks pLAM. Interestingly, 
DUX4 transcripts from chromosome 4q 
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evidence that chromosome looping can 
occur between the subtelomere of 4q and 
genes ~5 Mb away.27 It is also possible that 
these interactions might change with telo-
mere length and could influence muscle 
physiology.
Besides genes at chromosome 4q, 
other loci may contribute to FSHD, such 
as CRYM, which has been found to be 
expressed at high levels in some FSHD 
families,9,11 and has functions putatively 
misregulated in FSHD. Noteworthy 
are numerous case reports about the co-
occurrence of D4Z4 contraction and an 
independent myopathy.28-34 Figure 1 sum-
marizes some of the many possibilities 
in which short telomeres and other fac-
tors could cooperate in the production of 
FSHD symptoms.
In conclusion, the molecular mecha-
nism leading to FSHD is complex and 
not yet adequately understood. Current 
data and models are insufficient to fully 
explain this disease. Key assumptions, 
such as DUX4’s exclusive causative role, 
need to be unequivocally demonstrated. 
We believe that FSHD will prove to be 
a multifactorial disease, and that several 
several studies (e.g., 23), but a universal 
causal involvement in FSHD is ruled out 
because there are FSHD patients with 
deleted FRG2 on chromosome 4q, and 
by the absence of a phenotype when over-
expressed in vitro14 or in vivo.23 Although 
clearly not sufficient to cause FSHD, high 
expression of FRG2, whose function is still 
unknown, may synergize with DUX4 or 
other misregulated factors and contribute 
to disease in some patients. Other genes on 
chromosome 4q that may synergize with 
DUX4 and contribute to FSHD, possibly 
each only in a subset of patients, include 
FRG1, DUX4c and FAT1. FRG1 has been 
found elevated in FSHD cells and muscle 
by some investigators (e.g., 23), but not by 
others (e.g., 11,19), and FRG1 has been 
reported to cause an FSHD-like pheno-
type when highly overexpressed in mice.24 
DUX4c protein is identical to DUX4 
(outside of having a different C-terminus), 
and inhibits differentiation when overex-
pressed in myoblasts.25 Hypomorphic 
FAT1 alleles cause FSHD-like symptoms 
in mice and FAT1 levels are reduced in a 
subset of fetuses with D4Z4 contraction.26 
There is at least one study providing some 
FSHD in individuals expressing DUX4, 
and/or factors working synergistically 
with DUX4 to drive disease progression. 
Different factors and different mecha-
nisms in different individuals/fami-
lies would help explain the difficulty to 
detect an FSHD-specific signature in 
large cohorts. The simplest case would be 
increasing the dose of DUX4 by adding a 
second contracted allele, which has been 
suggested by unusually high numbers of 
compound heterozygous FSHD patients 
in several Italian families.8 Another way to 
increase DUX4 dosage would be a short 
telomere at 4q. We showed in a well-con-
trolled cell culture model that transcrip-
tion of DUX4 and FRG2 (centromeric of 
D4Z4) on contracted alleles is strongly 
upregulated by telomere shortening.18 
Telomere length not only decreases with 
aging (and could therefore explain delayed 
onset and progression of FSHD), but is 
also highly variable between individuals. 
For example, if the contracted 4q allele 
is paternal in origin, the length of the 
4q telomere in the sperm fertilizing the 
embryo could be dramatically different 
between siblings.22 This might partially 
explain cases in which siblings carrying 
the same contracted 4q allele nonethe-
less exhibit dramatically different ages of 
onset or severity of symptoms.
The mechanism by which telomere 
length affects gene expression at 4q35 
remains to be determined. It is likely that 
telomere length influences the epigenetic 
landscape in this region, e.g., that het-
erochromatin spreading from telomeres 
decreases during their shortening with 
increased age. In this scenario, normal-
sized D4Z4 repeats would act as a repres-
sor, so that the subtelomeric genes would 
be repressed regardless of telomere length. 
This repressor function would be reduced 
when < 11 repeats were present (and lost 
completely with 1–3 repeats). Expression 
could then increase with telomere short-
ening as heterochromatin spreading from 
the telomere diminished as telomeres 
shortened.
Theoretically, telomere length regu-
lated genes other than DUX4 may con-
tribute to FSHD as well. These might 
be located on chromosome 4q, such as 
FRG2, or other chromosomes. FRG2 has 
been found elevated in FSHD samples in 
Figure 1. Possible mechanisms in FSHd. By itself, duX4 expression from a contracted allele might 
not be sufficient to cause FSHd symptoms (A). Short telomeres would increase expression, but 
still might not be sufficient (B). A variety of additional factors could cooperate with duX4 to in-
crease muscle toxicity and produce weakness. A far from exhaustive list could include compound 
heterozygosity (having two contracted alleles, each increasing the dose of duX4 expression so 
the total was sufficient to exceed a threshold, (C), and other conditions that compromised muscle 
function (such as a subclinical myopathy (D, E), or the increased expression of other factors that 
by themselves produced decreased muscle reserve but not overt symptoms: (F-H). telomere 
length could modulate the age of onset and severity of symptoms by influencing duX4 levels or 
the level of other genes.
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